Home › Trials › NCT04056247

Algorithm to predict treatment outcomes in advanced cancer patients

PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Observational OncoHost Ltd. · NCT04056247

This study is testing a new tool to help doctors predict how well standard treatments will work for patients with advanced lung cancer and melanoma.

Quick facts

Study typeObservational
Enrollment2000 (estimated)
Ages18 Years and up
SexAll
SponsorOncoHost Ltd. Industry-sponsored
Locations41 sites (Birmingham, Alabama and 40 other locations)
Trial IDNCT04056247 on ClinicalTrials.gov

What this trial studies

This observational study aims to develop an algorithm that predicts treatment outcomes for patients with stage IV non-small cell lung cancer (NSCLC) and malignant melanoma. Patients will receive standard cancer treatments while providing blood samples and clinical data, which will be used to create and validate the prediction algorithm. The study seeks to identify metabolic pathways that may lead to improved therapeutic options, ultimately assisting physicians in making informed treatment decisions.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with stage IV NSCLC or stage IV malignant melanoma who meet specific health criteria.

Not a fit: Patients with concurrent active malignancies or significant mental impairments may not benefit from this study.

Why it matters

Potential benefit: If successful, this algorithm could help tailor cancer treatments to individual patients, potentially improving their outcomes.

How similar studies have performed: Other studies have explored predictive algorithms in oncology, showing promise in improving treatment outcomes, but this specific approach is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Cancer patients with stage IV NSCLC or stage IV malignant melanoma
* Patient must have at least one measurable lesion and the relevant images in order to enable assessment of response
* ECOG PS - 0/1-2
* Normal hematologic, renal and liver function:

  1. Absolute neutrophil count higher than 1500/mm3
  2. Platelets count higher than 100,000/mm3
  3. haemoglobin higher than 9 g/dL
  4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min
  5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit.

Exclusion Criteria:

* Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug
* Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Where this trial is running

Birmingham, Alabama and 40 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Stage IV Non-small Cell Lung CancerStage IV Malignant MelanomaStage IV Small Cell Lung CancerStage III Malignant Melanoma
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.